Mechanistic Connections between Glucose/Lipid Disturbances and Weight Gain induced by Antipsychotic Drugs

Abel, 2001, Adipose‐selective targeting of the GLUT4 gene impairs insulin action in muscle and liver, Nature, 409, 729, 10.1038/35055575 Allison, 1999, Antipsychotic‐induced weight gain: A comprehensive research synthesis, Am. J. Psychiatry, 156, 1686 Almeras, 2004, Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics, J. Clin. Psychiatry, 65, 557, 10.4088/JCP.v65n0417 2004, Consensus development conference on antipsychotic drugs and obesity and diabetes, Diabetes Care, 27, 596, 10.2337/diacare.27.2.596 Aravagiri, 1995, Distribution of fluphenazine and its metabolites in brain regions and other tissues of rat, Neuropsychopharmacology, 13, 235, 10.1016/0893-133X(95)00070-T Ardizzone, 2001, Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine, Brain Res., 923, 82, 10.1016/S0006-8993(01)03026-8 Ardizzone, 2002, Inhibition of neuronal glucose transport by calcium channel antagonists, Rec Res. Dev. Neurochem., 5, 103 Arjona, 2004, An animal model of antipsychotic‐induced weight gain, Behav. Brain Res., 152, 121 Arneson, 1964, Phenothiazine derivatives and glucose metabolism, J. Neuropsychiatry, 5, 181 Arranz, 2004, Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic‐naïve first‐episode schizophrenia patients, J. Clin. Psychiatry, 65, 1335, 10.4088/JCP.v65n1007 Ashrafi, 2003, Genome‐wide RNAi analysis of Caenorhabditis elegans fat regulatory genes, Nature, 421, 268, 10.1038/nature01279 Atmaca, 2003, Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics, J. Clin. Psychiatry, 64, 598, 10.4088/JCP.v64n0516 Baldessarini, 1993, Tissue concentrations of clozapine and its metabolites in the rat, Neuropsychopharmacology, 9, 117, 10.1038/npp.1993.50 Baptista, 2001, Metformin in the obesity associated to antipsychotic drug administration: A pilot study, J. Clin. Psychiatry, 62, 653, 10.4088/JCP.v62n0813b Baptista, 2002, Obesity and related metabolic abnormalities during antipsychotic drug administration: Mechanisms, management and research perspectives, Pharmacopsychiatry, 35, 205, 10.1055/s-2002-36391 Baptista, 1987, Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved?, Pharmacol. Biochem. Behav., 27, 399, 10.1016/0091-3057(87)90340-6 Baquer, 1988, Function and regulation of the pentose phosphate pathway in brain, Curr. Topics Cell. Reg., 29, 265, 10.1016/B978-0-12-152829-4.50008-2 Basile, 2002, −759C/T genetic variation of 5‐HT2C receptor and clozapine‐induced weight gain, Lancet, 360, 1790, 10.1016/S0140-6736(02)11706-5 Basile, 2001, Genetic dissection of atypical antipsychotic‐induced weight gain: Novel preliminary data on the pharmacogenetic puzzle, J. Clin. Psychiatry, 62, 45 Baukrowitz, 2000, KATP channels: Linker between phospholipids metabolism and excitability, Biochem. Pharmacol., 60, 735, 10.1016/S0006-2952(00)00267-7 Baymiller, 2002, Serum glucose and lipid changes during the course of clozapine treatment: The effect of concurrent b‐adrenergic antagonist treatment, Schizophr. Res., 59, 49, 10.1016/S0920-9964(02)00158-5 Bell, 1996, Glucokinase mutations, insulin secretion, and diabetes mellitus, Annu. Rev. Physiol., 58, 171, 10.1146/annurev.ph.58.030196.001131 Benvenga, 1997, Increased food consumption by clozapine, but not by olanzapine, in satiated rats, Drug Dev. Res., 41, 48, 10.1002/(SICI)1098-2299(199705)41:1<48::AID-DDR6>3.0.CO;2-S Bernstein, 1987, Induction of obesity by psychotropic drugs, Ann. N. Y. Acad. Sci., 499, 203, 10.1111/j.1749-6632.1987.tb36212.x Brady, 1989, Weight gain associated with psychotropic drugs, South. Med. J., 82, 611, 10.1097/00007611-198905000-00017 Bustillo, 1996, Differential effect of clozapine on weight gain: A controlled study, Am. J. Psychiatry, 153, 817, 10.1176/ajp.153.6.817 Carling, 2004, The AMP‐activated protein kinase cascade—a unifying system for energy control, Trends Biochem. Sci., 29, 18, 10.1016/j.tibs.2003.11.005 Casey, 2004, Dyslipidemia and atypical antipsychotic drugs, J. Clin. Psychiatry, 65, 27 Casey, 2001, The pharmacology of weight gain with antipsychotics, J. Clin. Psychiatry, 62, 4 Cederberg, 2001, FOXC2 is a winged helix gene that counteracts obesity, hypertriglyceridemia, and diet‐induced insulin resistance, Cell, 106, 563, 10.1016/S0092-8674(01)00474-3 Clement, 1995, Genetic variation in the beta 3‐adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity, N. Engl. J. Med., 333, 352, 10.1056/NEJM199508103330605 Cohen, 1992, Differences between antipsychotic drugs in persistence of brain levels and behavioral effects, Psychopharmacology, 108, 338, 10.1007/BF02245121 Cohen, 1990, Weight gain associated with clozapine, Am. J. Psychiatry, 147, 503, 10.1176/ajp.147.4.503 Correll, 2004, Pharmacogenetics of antipsychotic‐induced weight gain, Psychopharmacology, 174, 477, 10.1007/s00213-004-1949-9 Corton, 1995, 5‐Aminoimidazole‐4 carboxamide ribonucleoside: A specific method for activated AMP‐activated protein kinase in intact cells?, Eur. J. Biochem., 229, 558, 10.1111/j.1432-1033.1995.tb20498.x Curzon, 1997, Appetite suppression by commonly used drugs depends on 5‐HT receptors but not on 5‐HT availability, Trends Pharmacol. Sci., 18, 21, 10.1016/S0165-6147(96)01003-6 Czobor, 2002, Antipsychotic‐induced weight gain and therapeutic response: A differential association, J. Clin. Psychopharmacol., 22, 244, 10.1097/00004714-200206000-00003 Despres, 1989, Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women, Diabetes, 38, 304, 10.2337/diabetes.38.3.304 Deutch, 1991, Mechanisms of action of atypical antipsychotic drugs, 4, 121 2004, An update on type 2 diabetes in youth from the National Diabetes Education Program, Pediatrics, 114, 259, 10.1542/peds.114.1.259 Dwyer, 2002, Psychoactive drugs affect glucose transport and the regulation of glucose metabolism, Int. Rev. Neurobiol., 51, 503, 10.1016/S0074-7742(02)51015-1 Dwyer, 2001, Glucose metabolism in relation to schizophrenia and antipsychotic drug treatment, Ann. Clin. Psychiatry, 13, 103, 10.3109/10401230109148955 Dwyer, 2003, Induction of hyperglycemia in mice by atypical antipsychotic drugs in relation to glucose metabolism, Pharmacol. Biochem. Behav., 75, 255, 10.1016/S0091-3057(03)00079-0 Dwyer, 1999, Dopamine receptor antagonists modulate glucose uptake in rat pheochromocytoma (PC12) cells, Neurosci. Lett., 274, 151, 10.1016/S0304-3940(99)00712-0 Dwyer, 1999, Antipsychotic drugs affect glucose uptake and the expression of glucose transporters in PC12 cells, Prog. Neuro‐Psychopharmacol. Biol. Psychiatry, 23, 69, 10.1016/S0278-5846(98)00092-X Efrat, 1994, The pancreatic beta‐cell glucose sensor, Trends Biochem. Sci., 19, 535, 10.1016/0968-0004(94)90056-6 Ellingrod, 2002, CYP2D6 polymorphisms and atypical antipsychotic weight gain, Psychiatr. Genet., 12, 55, 10.1097/00041444-200203000-00008 Emorine, 1994, The human beta 3‐adrenoceptor: The search for a physiological function, Trends Pharmacol. Sci., 15, 3, 10.1016/0165-6147(94)90118-X Faurbye, 1970, The structural and biochemical basis of movement disorders in treatment with neuroleptic drugs and in extrapyramidal diseases, Compr. Psychiatry, 11, 205, 10.1016/0010-440X(70)90166-5 Fontaine, 2001, Estimating the consequences of antipsychotic‐induced weight gain on health and mortality rate, Psychiatry Res., 101, 277, 10.1016/S0165-1781(01)00234-7 Fulop, 2003, Hyperleptinemia, visceral adiposity, and decreased glucose tolerance in mice with a targeted disruption of the histidine decarboxylase gene, Endocrinology, 144, 4306, 10.1210/en.2003-0222 Gaulin, 1999, Clozapine‐associated elevation in serum triglycerides, Am. J. Psychiatry, 156, 1270 Ghaeli, 1995, Elevated serum triglycerides on clozapine resolve with risperidone, Pharmacotherapy, 15, 382 Ghaeli, 1996, Serum triglyceride levels in patients treated with clozapine, Am. J. Health Syst. Pharm., 53, 2079, 10.1093/ajhp/53.17.2079 Gordon, 1964, Weight change during and after hospital treatment, Arch. Gen. Psychiatry, 10, 115, 10.1001/archpsyc.1964.01720200083012 Gotto, 2002, High‐density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease, Am. Heart J., 144, S33, 10.1067/mhj.2002.130301 Goudie, 2003, H1‐Histamine receptor affinity predicts short‐term weight gain for typical and atypical antipsychotic drugs, Neuropsychopharmacology, 28, 2209, 10.1038/sj.npp.1300291 Grundy, 1998, Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome, Am. J. Cardiol., 81, 18B, 10.1016/S0002-9149(98)00033-2 Gupta, 1999, Olanzapine: Weight gain and therapeutic efficacy, J. Clin. Psychopharmacol., 19, 273, 10.1097/00004714-199906000-00014 Hagg, 1998, Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications, J. Clin. Psychiatry, 59, 294, 10.4088/JCP.v59n0604 Hajduch, 2001, Protein kinase B (PKB/Akt)—a key regulator of glucose transport?, FEBS Lett., 492, 199, 10.1016/S0014-5793(01)02242-6 Hardie, 2003, Management of cellular energy by the AMP‐activated protein kinase system, FEBS Lett., 546, 113, 10.1016/S0014-5793(03)00560-X Hartfield, 2003, Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat, Psychopharmacology, 167, 115, 10.1007/s00213-002-1368-8 Hartfield, 2003, Serotonergic and histaminergic mechanisms involved in intralipid drinking?, Pharmacol. Biochem. Behav., 76, 251, 10.1016/S0091-3057(03)00221-1 Haupt, 2005, Plasma leptin and adiposity during antipsychotic treatment of schizophrenia, Neuropsychopharmacology, 30, 184, 10.1038/sj.npp.1300563 Haupt, 2001, Hyperglycemia and antipsychotic medications, J. Clin. Psychiatry, 62, 15 Henderson, 2000, Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five‐year naturalistic study, Am. J. Psychiatry, 157, 975, 10.1176/appi.ajp.157.6.975 Henderson, 2002, Schizophrenia and diabetes, Int. Rev. Neurobiol., 51, 481, 10.1016/S0074-7742(02)51014-X Hiles, 1956, Hyperglycemia and glycosuria following chlorpromazine therapy, JAMA, 162, 1651, 10.1001/jama.1956.02970350067022 Hong, 2002, Genetic variant of the histamine‐1 receptor (glu349asp) and body weight change during clozapine treatment, Psychiatr. Genet., 12, 169, 10.1097/00041444-200209000-00009 Hong, 2001, Genetics variants of the serotonin system and weight change during clozapine treatment, Pharmacogenetics, 11, 265, 10.1097/00008571-200104000-00010 2004, Type 2 diabetes in the young: The evolving epidemic, Diabetes Care, 27, 1798, 10.2337/diacare.27.7.1798 Jonkers, 2001, Hypertriglyceridemia: Associated risks and effect of drug treatment, Am. J. Cardiovasc. Drugs, 1, 455, 10.2165/00129784-200101060-00005 Kaliner, 1992, Nonsedating antihistamines: Pharmacology, clinical efficacy and adverse effects, Am. Fam. Physician, 45, 1337 Kalucy, 1980, Drug‐induced weight gain, Drugs, 19, 268, 10.2165/00003495-198019040-00002 Kather, 1972, Interrelationship and control of glucose metabolism and lipogenesis in isolated fat‐cells, Biochem. J., 128, 1097, 10.1042/bj1281097 Kaur, 2002, Studies on modulation of feeding behavior by atypical antipsychotics in female mice, Prog. Neuropsychopharmacol. Biol. Psychiatry, 26, 277, 10.1016/S0278-5846(01)00266-4 Kelly, 1998, Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months, J. Child Adolesc. Psychopharmacol., 8, 151, 10.1089/cap.1998.8.151 Kirk, 2004, Ziprasidone suppresses olanzapine‐induced increases in ingestive behaviour in the rat, Eur. J. Pharmacol., 505, 253, 10.1016/j.ejphar.2004.10.015 Kobayashi, 2000, Inhibition by various antipsychotic drugs of the G‐protein‐activated inwardly rectifying K+ (GIRK) channels expressed in Xenopus oocytes, Br. J. Pharmacol., 129, 1716, 10.1038/sj.bjp.0703224 Koller, 2002, Olanzapine‐associated diabetes mellitus, Pharmacotherapy, 22, 841, 10.1592/phco.22.11.841.33629 Koller, 2001, Clozapine‐associated diabetes, Am. J. Med., 111, 716, 10.1016/S0002-9343(01)01000-2 Kornhuber, 1999, Persistence of haloperidol in human brain tissue, Am. J. Psychiatry, 156, 885, 10.1176/ajp.156.6.885 Koro, 2002, An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients, Arch. Gen. Psychiatry, 59, 1021, 10.1001/archpsyc.59.11.1021 Krentz, 2003, Lipoprotein abnormalities and their consequences for patients with type 2 diabetes, Diabetes Obes. Metab., 5, S19, 10.1046/j.1462-8902.2003.0310.x Kroeze, 2003, H1‐Histamine receptor affinity predicts short‐term weight gain for typical and atypical antipsychotic drugs, Neuropsychopharmacology, 28, 519, 10.1038/sj.npp.1300027 Lawlor, 2001, PKB/Akt: A key mediator of cell proliferation, survival and insulin responses?, J. Cell Sci., 114, 2903, 10.1242/jcs.114.16.2903 Leadbetter, 1992, Clozapine‐induced weight gain: Prevalence and clinical relevance, Am. J. Psychiatry, 149, 68, 10.1176/ajp.149.1.68 Levin, 2002, CNS sensing and regulation of peripheral glucose levels, Int. Rev. Neurobiol., 51, 219, 10.1016/S0074-7742(02)51007-2 Lizcano, 2004, LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR‐1, EMBO J., 23, 833, 10.1038/sj.emboj.7600110 Lindenmayer, 2003, Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics, Am. J. Psychiatry, 160, 290, 10.1176/appi.ajp.160.2.290 Lu, 2004, Olanzapine produces trophic effects in vitro and stimulates phosphorylation of Akt/PKB, ERK1/2, and the mitogen‐activated protein kinase p38, Brain Res., 1011, 58, 10.1016/j.brainres.2004.03.018 Lu, 2005, Neurotrophic effects of psychotropic drugs: Significance for schizophrenia and other neurodevelopmental disorders Masaki, 2004, Involvement of hypothalamic histamine H1 receptor in the regulation of feeding and obesity, Diabetes, 53, 2250, 10.2337/diabetes.53.9.2250 Masaki, 2001, Targeted disruption of histamine H1‐receptor attenuates regulatory effects of leptin on feeding, adiposity, and UCP family in mice, Diabetes, 50, 385, 10.2337/diabetes.50.2.385 Matschinsky, 1997, Essential biochemical design features of the fuel‐sensing system in pancreatic beta‐cells, Chem. Biol., 4, 249, 10.1016/S1074-5521(97)90068-5 McIntyre, 2001, Mechanisms of antipsychotic‐induced weight gain, J. Clin. Psychiatry, 62, 23 McKay, 2003, C. elegans: A model for exploring the genetics of fat storage, Dev. Cell, 4, 131, 10.1016/S1534-5807(02)00411-2 Melkersson, 2001, Insulin and leptin levels in patients with schizophrenia or related psychoses—A comparison between two different antipsychotic agents, Psychopharmacology, 154, 205, 10.1007/s002130000639 Melkersson, 2000, Elevated levels of insulin, leptin, and blood lipids in olanzapine‐treated patients with schizophrenia or related psychoses, J. Clin. Psychiatry, 61, 742, 10.4088/JCP.v61n1006 Meltzer, 1999, The role of serotonin in antipsychotic drug action, Neuropsychopharmacology, 21, 106S, 10.1016/S0893-133X(99)00046-9 Meltzer, 2003, Clozapine‐induced weight gain predicts improvement in psychopathology, Schizophr. Res., 59, 19, 10.1016/S0920-9964(01)00326-7 Menza, 2004, Managing atypical antipsychotic‐associated weight gain: 12‐month data on a multimodal weight control program, J. Clin. Psychiatry, 65, 471, 10.4088/JCP.v65n0404 Meyer, 2001, Novel antipsychotics and severe hyperlipidemia, J. Clin. Psychopharmacol., 21, 369, 10.1097/00004714-200108000-00003 Meyer, 2002, A retrospective comparison of weight, lipid, and glucose changes between risperidone‐ and olanzapine‐treated inpatients: Metabolic outcomes after 1 year, J. Clin. Psychiatry, 63, 425, 10.4088/JCP.v63n0509 Meyer, 2004, The effects of antipsychotic therapy on serum lipids: A comprehensive review, Schizophr. Res., 70, 1, 10.1016/j.schres.2004.01.014 Miller, 2000, Serum triglycerides, the liver and the pancreas, Curr. Opin. Lipidol., 11, 377, 10.1097/00041433-200008000-00006 Minokoshi, 2004, AMP‐kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus, Nature, 428, 569, 10.1038/nature02440 Minokoshi, 2003, Tissue‐specific ablation of the GLUT4 glucose transporter or the insulin receptor challenges assumptions about insulin action and glucose homeostasis, J. Biol. Chem., 278, 33609, 10.1074/jbc.R300019200 Montastruc, 1992, Calcium channel blockers and prevention of migraine, Pathol. Biol. (Paris), 40, 381 Morisco, 2005, Akt mediates the cross‐talk between β‐adrenergic and insulin receptors in neonatal cardiomyocytes, Circ. Res., 96, 180, 10.1161/01.RES.0000152968.71868.c3 Morrison, 2002, Metformin for weight loss in pediatric patients taking psychotropic drugs, Am. J. Psychiatry, 159, 655, 10.1176/appi.ajp.159.4.655 Moxham, 1996, Insulin action impaired by deficiency of the G‐protein subunit Giα2, Nature, 379, 840, 10.1038/379840a0 Mueller, 2004, Pharmacogenetics of antipsychotic‐induced weight gain, Pharmacol. Res., 49, 309, 10.1016/j.phrs.2003.05.001 Mukherjee, 1985, Possible association between tardive dyskinesia and altered carbohydrate metabolism, Arch. Gen. Psychiatry, 42, 205, 10.1001/archpsyc.1985.01790250099016 Muller, 1991, Chlorpromazine and related phenothiazines inhibit the ATP‐sensitive K+ channel, Eur. J. Pharmacol., 198, 101, 10.1016/0014-2999(91)90569-C Neel, 1962, Diabetes mellitus: A “thrifty” genotype rendered detrimental by “progress”?, Am. J. Human Genetics, 14, 353 Newcomer, 2004, Abnormalities of glucose metabolism associated with atypical antipsychotic drugs, J. Clin. Psychiatry, 65, 36 Newcomer, 2002, Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia, Arch. Gen. Psychiatry, 59, 337, 10.1001/archpsyc.59.4.337 Nonogaki, 2000, New insights into sympathetic regulation of glucose and fat metabolism, Diabetologia, 43, 533, 10.1007/s001250051341 Nonogaki, 1998, Leptin‐independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5‐HT2C receptor gene, Nature Med., 4, 1152, 10.1038/2647 Norman, 1955, Glycemic effects of chlorpromazine in the mouse hamster and rat, Proc. Soc. Exp. Biol. Med., 90, 89, 10.3181/00379727-90-21947 Olesen, 1998, Therapeutic drug monitoring of clozapine treatment, Clin. Pharmacokinet., 34, 497, 10.2165/00003088-199834060-00005 Olesen, 1999, Olanzapine serum concentrations in psychiatric patients given standard doses: The influence of comedication, Ther. Drug Monit., 21, 87, 10.1097/00007691-199902000-00013 Osser, 1999, Olanzapine increases weight and serum triglyceride levels, J. Clin. Psychiatry, 60, 767, 10.4088/JCP.v60n1109 Pijl, 1996, Body weight change as an adverse effect of drug treatment. Mechanisms and management, Drug Safety, 14, 329, 10.2165/00002018-199614050-00005 Planansky, 1958, Changes in weight in patients receiving a “tranquilizing” drug, Psychiatr. Q., 32, 289, 10.1007/BF01561635 Pouzet, 2003, Chronic treatment with antipsychotics in rats as a model for antipsychotic‐induced weight gain in human, Pharmacol. Biochem. Behav., 75, 133, 10.1016/S0091-3057(03)00042-X Povlsen, 1985, Tolerability and therapeutic effect of clozapine, Acta Psychiatr. Scand., 71, 176, 10.1111/j.1600-0447.1985.tb01268.x Prusty, 2002, Activation of MEK/ERK signaling promotes adipogenesis by enhancing peroxisome proliferator‐activated receptor gamma (PPARgamma) and C/EBPalpha gene expression during the differentiation of 3T3‐L1 preadipocytes, J. Biol. Chem., 277, 46226, 10.1074/jbc.M207776200 Randle, 1980, The biochemical basis of the relation between glucose and fatty acid metabolism, Acta Chir. Scand. Suppl., 498, 111 Randle, 1995, Metabolic fuel selection: General integration at the whole‐body level, Proc. Nutr. Soc., 54, 317, 10.1079/PNS19950057 Randle, 1963, The glucose fatty‐acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus, Lancet, i, 785, 10.1016/S0140-6736(63)91500-9 Reynolds, 2002, Association of antipsychotic drug‐induced weight gain with a 5‐HT2C receptor gene polymorphism, Lancet, 359, 2086, 10.1016/S0140-6736(02)08913-4 Reynolds, 2003, Polymorphism of the promoter region of the serotonin 5‐HT2C receptor gene and clozapine‐induced weight gain, Am. J. Psychiatry, 160, 677, 10.1176/appi.ajp.160.4.677 Rietschel, 1997, Efficacy and side‐effects of clozapine not associated with variation in the 5‐HT2C receptor, Neuroreport, 8, 1999, 10.1097/00001756-199705260-00040 Robertson, 2000, Olanzapine concentrations in clinical serum and postmortem blood specimens — when does therapeutic become toxic?, J. Forensic Sci., 45, 418, 10.1520/JFS14697J Russell, 2001, Body weight gain associated with atypical antipsychotics, CNS Drugs, 15, 537, 10.2165/00023210-200115070-00004 Rutter, 2003, Roles of 5′‐AMP‐activated protein kinase (AMPK) in mammalian glucose homeostasis, Biochem. J., 375, 1, 10.1042/bj20030048 Saari, 2004, Hyperlipidemia in persons using antipsychotic medication: A general population‐based birth cohort study, J. Clin. Psychiatry, 65, 547, 10.4088/JCP.v65n0415 Sakel, 1938, The methodological use of hypoglycemia in the treatment of psychoses, Am. J. Psychiatry., 94, 111, 10.1176/ajp.94.1.111 Schuit, 2001, Glucose sensing in pancreatic beta‐cells: A model for the study of other glucose‐regulated cells in gut, pancreas, and hypothalamus, Diabetes, 50, 1, 10.2337/diabetes.50.1.1 Schwartz, 2003, Is the energy homeostasis system inherently biased toward weight gain?, Diabetes, 52, 232, 10.2337/diabetes.52.2.232 Sheitman, 1999, Olanzapine‐induced elevation of plasma triglyceride levels, Am. J. Psychiatry, 156, 1471 Simon, 1951, Glucose tolerance in chronic schizophrenia and senile states, Arch. Neurol. Psychiatry, 65, 717, 10.1001/archneurpsyc.1951.02320060060007 Sowell, 2002, Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo, J. Clin. Endocrinol. Metab., 87, 2918, 10.1210/jc.87.6.2918 Stenbit, 1997, GLUT4 heterozygous knockout mice develop muscle insulin resistance and diabetes, Nature Med., 3, 1096, 10.1038/nm1097-1096 Susulic, 1995, Targeted disruption of the β3‐adrenergic receptor gene, J. Biol. Chem., 270, 29483, 10.1074/jbc.270.49.29483 Sze, 2000, Food and metabolic signaling defects in a Caenorhabditis elegans serotonin‐synthesis mutant, Nature, 403, 560, 10.1038/35000609 Takahashi, 2002, Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype, J. Clin. Invest., 110, 1791, 10.1172/JCI15784 Tanoue, 2003, Insights into α1 adrenoceptor function in health and disease from transgenic animal studies, Trends Endocr. Metab., 14, 107, 10.1016/S1043-2760(03)00026-2 Tecott, 1995, Eating disorder and epilepsy in mice lacking 5‐HT2C serotonin receptors, Nature, 374, 542, 10.1038/374542a0 Theisen, 2001, Prevalence of obesity in adolescent and young adult patients with and without schizophrenia and in relationship to antipsychotic medication, J. Psychiatr. Res., 35, 339, 10.1016/S0022-3956(01)00041-3 Tollefson, 1983, Nonketotic hyperglycemia associated with loxapine and amoxapine: Case report, J. Clin. Psychiatry, 44, 347 Toskes, 1990, Hyperlipidemic pancreatitis, Gastroenterol. Clin. North Am., 19, 783, 10.1016/S0889-8553(21)00513-6 Toyota, 2002, Behavioral characterization of mice lacking histamine H3 receptors, Mol. Pharmacol., 61, 389, 10.1124/mol.62.2.389 Tsai, 2002, −759C/T genetic variation of 5‐HT2C receptor and clozapine‐induced weight gain, Lancet, 360, 1790, 10.1016/S0140-6736(02)11705-3 Ulrich, 1998, The relationship between serum concentration and therapeutic effects of haloperidol in patients with acute schizophrenia, Clin. Pharmacokinet., 34, 227, 10.2165/00003088-199834030-00005 Umbricht, 1994, Clozapine and weight gain, J. Clin. Psychiatry, 55, 157 Viollet, 2003, The AMP‐activated protein kinase α2 catalytic subunit controls whole‐body insulin sensitivity, J. Clin. Invest., 111, 91, 10.1172/JCI16567 Waitzkin, 1966, A survey for unknown diabetics in a mental hospital. II. Men from age fifty, Diabetes, 15, 164, 10.2337/diab.15.3.164 Weigmann, 1999, Distribution of clozapine and desmethylclozapine between blood and brain in rats, Eur. Neuropsychopharmacology, 9, 253, 10.1016/S0924-977X(98)00036-4 Wetterling, 1999, Weight gain: Side effect of atypical neuroleptics?, J. Clin. Psychopharmacol., 19, 316, 10.1097/00004714-199908000-00006 Widen, 1995, Association of a polymorphism in the beta 3‐adrenergic receptor gene with features of the insulin resistance syndrome in Finns, N. Engl. J. Med., 333, 348, 10.1056/NEJM199508103330604 Wirshing, 2004, Schizophrenia and obesity: Impact of antipsychotic medications, J. Clin. Psychiatry, 65, 13 Wirshing, 2002, The effects of novel antipsychotics on glucose and lipid levels, J. Clin. Psychiatry, 63, 856, 10.4088/JCP.v63n1002 Wirshing, 1999, Novel antipsychotics: Comparison of weight gain liabilities, J. Clin. Psychiatry, 60, 358, 10.4088/JCP.v60n0602 Wood, 1986, Physiological functions of the pentose phosphate pathway, Cell. Biochem. Funct., 4, 241, 10.1002/cbf.290040403 Wu, 2000, Characterization of inhibition by risperidone of the inwardly rectifying K+ current in pituitary GH(3) cells, Neuropsychopharmacology, 23, 676, 10.1016/S0893-133X(00)00151-2 Yang, 2002, An mRNA splice variant of the AFX gene with altered transcriptional activity, J. Biol. Chem., 277, 8068, 10.1074/jbc.M106091200 Yazici, 1998, The effect of clozapine on glucose metabolism, Exp. Clin. Endocrinol. Diabetes, 106, 475, 10.1055/s-0029-1212019 Zarate, 2004, Effects of clozapine on behavioral and metabolic traits relevant for schizophrenia in two mouse strains, Psychopharmacology, 171, 162, 10.1007/s00213-003-1553-4 Zhang, 2003, Association of −2548G/A functional polymorphism in the promoter region of leptin gene with antipsychotic agent‐induced weight gain, Zhonghua Yi Xue Za. Zhi., 83, 2119 Zhang, 2004, Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia, Br. J. Psychiatry, 184, 58, 10.1192/bjp.184.1.58 Zimmermann, 2003, Epidemiology, implications and mechanisms underlying drug‐induced weight gain in psychiatric patients, J. Psychiatr. Res., 37, 193, 10.1016/S0022-3956(03)00018-9